Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes

References

• Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol.95(1), 26–36 (1996).
   PubMed Web of Science ®Google Scholar
• Olivieri NF. The β-thalassemias. N. Engl. J. Med.341(2), 99–109 (1999).
   PubMed Web of Science ®Google Scholar
• Pippard MJ, Warner GT, Callender ST, Weatherall DJ. Iron absorption and loading in β-thalassemia intermedia. Lancet2(8147), 819–821 (1979).
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol.23(30), 7594–7603 (2005).
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Cutler CS et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood109(10), 4586–4588 (2007).
   PubMed Web of Science ®Google Scholar
• Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am. J. Hematol.83(8), 611–613 (2008)
   PubMed Web of Science ®Google Scholar
• Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol.120(2), 187–200 (2003).
   PubMed Web of Science ®Google Scholar
• Bennett JM. MDS Foundation’s Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am. J. Hematol.83(11), 858–861 (2008).
   PubMed Web of Science ®Google Scholar
• Pietrangelo A, Brissot P, Bonkovsky H et al. Design of an ongoing Phase I–II open label, dose escalation trial using the oral chelator deferasirox to treat iron overload in HFE-related hereditary hemochromatosis (HH). Blood109(11), 788a (2007).
   Google Scholar
• Arboretti R, Tognoni G, Alberti D. Italian Colaborative Group on Thalassaemia. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur. J. Clin. Pharmacol.56(12), 915–922 (2001).
   PubMed Web of Science ®Google Scholar
• Cohen A. Management of iron overload in the pediatric patient. Hematol. Oncol. Clin. North Am.1(3), 521–544 (1987).
   PubMedGoogle Scholar
• Payne K, Desrosiers M, Caro J et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion47(10), 1820–1829 (2007).
   PubMed Web of Science ®Google Scholar
• Nick H, Acklin P, Lattmann R et al. Development of tridentate iron chelators: From desferrithiocin to ICL670. Curr. Med. Chem.10(12), 1065–1076 (2003).
   PubMed Web of Science ®Google Scholar
• Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Séchaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J. Clin. Pharmacol.43(6), 565–572 (2003).
   PubMed Web of Science ®Google Scholar
• Piga A, Galanello R, Forni GL et al. Randomized Phase II trial of deferasirox (exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica91(7), 873–880 (2006).
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood107(9), 3455–3462 (2006).
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Onyekwere O, Porter J et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br. J. Haematol.136(3), 501–508 (2007).
   PubMed Web of Science ®Google Scholar
• Leitch H, Leger C, Goodman T et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin. Leuk.2(3), 205–211 (2008).
   Google Scholar
• Metzgeroth G, Dinter D, Schultheis B et al. Deferasirox in MDS patients with transfusion-caused iron overload – a Phase-II study. Ann. Hematol.88(4), 301–310 (2008).
   PubMed Web of Science ®Google Scholar
• Porter J, Galanello R, Saglio G et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur. J. Haematol.80(2), 168–176 (2008).
   PubMed Web of Science ®Google Scholar
• Cappellini M, El-Beshlawy A, Kattamis A et al. Efficacy and safety of deferasirox (Exjade®) in patients with transfusion-dependent anemias: 1-year results from the large, prospective, multicenter EPIC study. American Society of Hematology 50th Annual Meeting abstracts. Blood112(11), 1319 (2008).
   Google Scholar
• McLeod C, Fleeman N, Kirkham J et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol. Assess.13(1), iii–iv, ix–xi, 1–121 (2009).
   PubMed Web of Science ®Google Scholar
• Delea TE, Thomas SK, Baldi JF, Coates TD. Once dailyoral deferasirox (Exjade®, ICL670) versus infusional deferoxamine as iron chelation therapy in patients with sickle-cell disease receiving frequent transfusions: a cost–effectiveness analysis. Blood106, 5584 (2005).
   Google Scholar
• Delea TE, Thomas SK, Baladi JF, Phatak PD. Cost–effectiveness analysis of oral iron chelation therapy with deferasirox (Exjade®, ICL670) versus infusional chelation therapy with deferoxamine in patients with transfusion-dependent myelodysplastic syndrome. Blood106, 5585 (2005).
   Google Scholar
• Delea TE, El Ouagari K, Sofrygin O. Cost of current iron chelation infusion therapy and cost effectiveness of once-daily oral deferasirox in transfusion-dependent thalassemia patients in Canada. Presented at: American Society of Hematology 48th Annual Meeting, FL, USA, 3349 (2006).
   Google Scholar
• Delea T, Sofrygin O, Thomas S, Baladi JF, Phatak P, Coates TD. Cost–effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassemia patients: US healthcare system perspective. Pharmacoeconomics25, 329–342 (2007).
   PubMed Web of Science ®Google Scholar
• Delea TE, Sofrygin O, Baladi J-F et al. Sensitivity analysis on the cost–effectiveness of chelation therapy with deferasirox or deferoxamine in transfusion dependent thalassemia patients based on European costs. Presented at: European Hematology Association 11th Annual Congress. Amsterdam, The Netherlands, 15–18 June 2006.
   Google Scholar
• Calebro A, Delea TE, Sofrygin O et al. Cost–effectiveness of once-daily oral chelation therapy with deferasirox (Exjade®) versus infusional deferoxamine in transfusion dependent thalassemic patients: a Brazilian perspective. Presented at: European Hematology Association 11th Annual Congress. Amsterdam, The Netherlands, 15–18 June 2006.
   Google Scholar
• Karnon J, Akehurst R, Papo N. Cost utility analysis of deferasirox (Exjade®) versus deferoxamine (Desferal) for patients requiring iron chelation therapy in the United Kingdom. Presented at: European Hematology Association 11th Annual Congress. Amsterdam, The Netherlands, 15–18 June 2006.
   Google Scholar
• Karnon J, Akehurst R, Jewitt K, Ossa D. Cost utility analysis of deferasirox (Exjade®) versus deferoxamine (Desferal) for patients requiring iron chelation therapy in the United Kingdom. Presented at: European Hematology Association 12th Annual Congress. Vienna, Austria, 7–10 June 2007.
   Google Scholar
• Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr. Med. Res. Opin.24(6), 1609–1621 (2008).
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Decis. Making13(4), 322–338 (1993).
   PubMed Web of Science ®Google Scholar
• Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br. J. Haematol.121(6), 938–948 (2003).
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch. Intern. Med.163(14), 1637–1641 (2003).
   PubMed Web of Science ®Google Scholar
• Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br. J. Haematol.73(3), 403–409 (1989).
   PubMed Web of Science ®Google Scholar